Quantum Biopharma Ltd. has announced the filing of a supplement to its management information circular, addressing important details regarding its proposed share consolidation and voting power thresholds. This update is significant as it aims to provide clarity for shareholders ahead of the upcoming annual general and special meeting scheduled for November 10, 2026.

Based in Toronto, Quantum Biopharma Ltd. operates in the pharmaceutical preparations sector. The company is listed on the Nasdaq under the ticker QNTM. Quantum is dedicated to developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Recent filings include a Form 6-K submitted on November 5, 2026, and prior filings on October 8 and October 6 of the same year.

The recent filing states, "The Supplement corrects and restates the special resolution to be considered at the Meeting authorizing a consolidation of the Company’s class A multiple voting shares and class B subordinate voting shares." It further clarifies that fractional shares resulting from the consolidation will be rounded either up or down based on their value.

This update may affect shareholders of Quantum Biopharma, as it directly relates to their voting rights and the structure of their shareholdings. The company also emphasizes the importance of shareholder participation in the upcoming meeting, encouraging all to review the updated materials and submit their voting instructions.

Looking ahead, Quantum Biopharma will hold its annual general and special meeting on November 10, 2026, where shareholders will vote on the proposed resolutions. The filing does not specify any further steps beyond this meeting.